Phase 1 clinical experience with BLZ-100 for near-infrared fluorescence guided tumor resection

Julie Novak

doi:10.1364/OMP.2017.OmW3D.1

This website uses cookies to deliver some of our products and services as well as for analytics and to provide you a more personalized experience. Click here to learn more. By continuing to use this site, you agree to our use of cookies. We’ve also updated our Privacy Notice. Click here to see what’s new.

Allow All Cookies

Optical Molecular Probes, Imaging and Drug Delivery 2017

San Diego, California United States
2–5 April 2017
ISBN: 978-1-943580-25-5

From the session
Molecular Probes for Imaging and Therapy (OmW3D)

Phase 1 clinical experience with BLZ-100 for near-infrared fluorescence guided tumor resection

Julie Novak

Optics in the Life Sciences Congress
OSA Technical Digest (online) (Optical Society of America, 2017),
paper OmW3D.1
•https://doi.org/10.1364/OMP.2017.OmW3D.1

Get Citation
Copy Citation Text
J. Novak, "Phase 1 clinical experience with BLZ-100 for near-infrared fluorescence guided tumor resection," in Optics in the Life Sciences Congress, OSA Technical Digest (online) (Optical Society of America, 2017), paper OmW3D.1.

Export Citation
- BibTex
- Endnote (RIS)
- HTML
- Plain Text
Get PDF (165 KB)
Set citation alerts
Save article

Accessible

Open Access

Abstract

BLZ-100 is an optical contrast agent composed of chlorotoxin and indocyanine green. Clinical trials in multiple tumor types enabled tandem evaluation of BLZ-100 with clinical imaging devices. Safety and imaging data support further clinical development.

PDF Article

Privacy | Terms of Use

Abstract

Optical Molecular Probes, Imaging and Drug Delivery 2017

Login or Create Account